How Are Asset Managers Positioning Themselves Around Alkermes plc (NASDAQ:ALKS)?

3 min read | March 26, 2025 12:00 AM PDT | By Team Kalkine Media

How Are Asset Managers Positioning Themselves Around Alkermes plc (NASDAQ:ALKS)? — Image source: Shutterstock

Institutional Activity in Alkermes plc

Alkermes plc (NASDAQ:ALKS), a global biopharmaceutical company, has seen growing movement from institutional entities in recent months. According to the latest fourth-quarter filings, Natixis Advisors LLC boosted its position in Alkermes by more than thirty percent, totaling nearly fifty thousand shares. This development adds to the wider pattern of shifting institutional behavior surrounding the company.

Other financial firms mirrored this trend. Venturi Wealth Management LLC initiated a position, while Blue Trust Inc. reported a significant increase, resulting in a more than twentyfold rise in its ownership. Smartleaf Asset Management LLC also elevated its stake significantly. Institutional ownership now encompasses over ninety percent of the company’s shares, reinforcing its position within institutional portfolios.

Adjustments by Financial Institutions

The broad institutional movement reflects diverse strategies adopted during the period. EverSource Wealth Advisors LLC expanded its holding by more than double, while Cornerstone Investment Partners LLC entered with a new position. These holdings illustrate continued engagement from asset managers and capital groups aligned with the healthcare and biopharmaceutical sector.

This level of institutional involvement suggests ongoing monitoring of the company’s performance and developments within its product pipeline and commercial strategies. While ownership levels remain high, the diversity in stake size modifications illustrates both commitment and reassessment based on evolving operational factors.

Market Capitalization and Valuation Standing

Alkermes opened at a share price aligned with its typical trading range and continues to reflect solid valuation in terms of capitalization. Trading stability and balanced liquidity positions underpin its current standing, supported by consistent operational updates from the company.

Market capitalization and financial ratios place the company among other mid-cap entities in the biopharmaceutical space. Activity among key stakeholders in the market further aligns with its ongoing developments, including commercial sales of treatment options in mental health and addiction.

Strategic Focus and Industry Relevance

Alkermes operates in several specialized therapeutic areas, including treatments for alcohol and opioid dependence, as well as complex psychiatric disorders. Its research and development pipeline spans both late-stage and early-stage clinical programs.

Geographically, the company is active in the United States, Ireland, and additional global markets. Through its targeted focus on neurological and psychiatric conditions, the company continues to align product development with areas of public health relevance.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.